GlassScriptPhysician profile
David P Harris
NPI 1275822637
$1,996.13
in general payments reported to CMS, 2019-2025
11 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.61 · 2022: $238 · 2023: $221 · 2024: $526 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $456.61 | 2024-2025 | Percept PC Brainsense |
| Supernus Pharmaceuticals, INC. | $440.36 | 2022-2025 | Qelbree, Qelbree |
| Neuropace, INC. | $280.49 | 2023-2025 | |
| Lundbeck LLC | $207.45 | 2023-2025 | Rexulti |
| Ucb, INC. | $161.12 | 2022 | |
| Jazz Pharmaceuticals INC. | $137.89 | 2025 | |
| Sk Life Science, INC. | $120.38 | 2025 | |
| Neurelis, INC. | $95.72 | 2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $63.18 | 2022 | |
| Neurocrine Biosciences, INC. | $20.32 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.